NVO | tickerfilter.com

Fundamental analysis

45%

Profitability 64%

Dept financing 13%

Liquidity 33%

Performance 38%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.11%

1 Month

-22.31%

3 Months

-23.61%

6 Months

-34.70%

1 Year

-58.10%

2 Year

-71.35%

Key data

Stock price

$36.66

P/E Ratio

27.68

DAY RANGE

$35.85 - $36.95

EPS

$2.44

52 WEEK RANGE

$35.85 - $89.03

52 WEEK CHANGE

-$59.65

MARKET CAP

387.950 B

YIELD

1.68%

SHARES OUTSTANDING

3.390 B

DIVIDEND

$1.2751

EX-DIVIDEND DATE

03-30-2026

NEXT EARNINGS DATE

08-06-2025

BETA

0.58

PUBLIC FLOAT

AVERAGE 10 VOLUME

$44,818,120

AVERAGE 30 VOLUME

$31,442,345

Company detail

CEO: Lars F. Jørgensen
Region: US
Website: novonordisk.com
Employees: 54,400
IPO year: 1982

Issue type: American Depository Receipt (ADR’s)
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Novo Nordisk A/S engages in the research, development, manufacture, and marketing of pharmaceutical products. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in areas of haemophilia, growth disorders, and hormone replacement therapy. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

NVO - NOVO NORDISK A S